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Copyright © 200? JCBN Summary Recently, it is suggested that the use of nonsteroidal anti-inflammatory drugs
(NSAID) may contribute to the occurrence of cardiovascular events, while the formation of
atherosclerotic lesions is related to inflammation. Loxoprofen sodium, a non-selective NSAID,
becomes active after metabolism in the body and inhibits the activation of cyclooxygenase. We
fed apoE−/− mice a western diet from 8 to 16 weeks of age and administered loxoprofen sodium.
We measured atherosclerotic lesions at the aortic root. We examined serum levels of
cholesterol and triglycerides with HPLC, platelet aggregation, and urinary prostaglandin
metabolites with enzyme immune assay. Atherosclerotic lesion formation was reduced to
63.5% and 41.5% as compared to the control in male and female apoE−/− mice treated with
loxoprofen sodium respectively. Urinary metabolites of prostaglandin E2, F1α, and thromboxane
B2, and platelet aggregation were decreased in mice treated with loxoprofen sodium. Serum
levels of cholesterol and triglycerides were not changed. We conclude that loxoprofen sodium
reduced the formation of early to intermediate atherosclerotic lesions at the proximal aorta in
mice mediated by an anti-inflammatory effect.
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Introduction
As a result of progress in therapy for rheumatoid arthritis
(RA), cardiovascular events have become the major cause of
death in these patients. RA is associated with an increased
and accelerated vascular risk that results in lifespan reduc-
tion [1–3]. There is an association between disease activity
and cardiovascular risk in RA and other inflammatory dis-
orders, such as systemic lupus erythematosus (SLE) [1, 4, 5].
Several factors may be associated with accelerated arterio-
sclerosis in patients with RA or SLE. One factor may be the
disease itself, while others may include the pharmacological
therapies that patients with RA or SLE receive.
Rofecoxib, a highly selective cyclooxygenase(COX)-2
inhibitor, has recently been voluntarily withdrawn from the
market due to evidence from the APPROVe trial demon-
strating increased cardiovascular events after 18 monthsLoxoprofen Sodium Reduces Atherosclerosis
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of use. Combination therapy with the selective COX-2
inhibitors, valdecoxib and parecoxib increased the risk by
3.7-fold [6]. Concerns have been raised that a highly selec-
tive COX-2 inhibition may promote cardiovascular events
by inhibiting prostacyclin and inducing a prothrombotic
state [7]. In contrast, inhibition of COX-1 mediated produc-
tion of platelet thromboxane (Tx) by aspirin reduces the risk
of myocardial infarction and stroke [8].
Selective COX-2 inhibitors are the major anti-pain drugs
used in western countries. Loxoprofen sodium is a pro-drug
of phenyl mefenamic acid and a non-selective COX
inhibitor. It is the dominant anti-pain drug in Japan and
most frequently prescribed in East Asian countries [9]. In
view of the reports related to COX-2 selective inhibitors
in the USA, the adverse effects of nonsteroidal anti-
inflammatory drugs (NSAIDs) associated with cardiovascular
disease were surveyed in Japan in June 2005. However, no
evidence was found of any adverse effects of loxoprofen
sodium associated with cardiovascular events. The
Pharmaceutical and Medical Devices Agency in Japan
concluded that it was not necessary to perform safety mea-
sures for loxoprofen sodium against cardiovascular events
[www.info.pmda.go.jp].
It has been reported that selective inhibition of COX-1
attenuates atherosclerosis in apoE−/− mice [10]. However,
reports on the effect of selective COX-2 inhibition on the
development of atherosclerosis in murine models have
been mixed with decreased, increased or unchanged
atherosclerotic lesions all noted [11, 12]. The divergence
in the results may be the consequence of differences in
experimental design, including efficacy and selectivity of the
inhibitors, gender of the mice and stage of atherosclerotic
lesions.
The surveillance study of adverse effects of loxoprofen
sodium in Japan and these studies of non-selective inhibition
of COX inhibition on the development of atherosclerosis
in animal models demonstrate the ability of non-selective
COX inhibition with loxoprofen sodium to reduce early
and intermediate atherosclerotic lesion formation in apoE−/−
mice, supporting the efficacy of anti-inflammatory approaches
in the prevention of atherosclerosis.
Materials and Methods
Healthy volunteers
Three healthy men participated in this study. They
received blood examinations and collected urine for 24 h
before administration of loxoprofen sodium. After receiving
loxoprofen sodium 60 mg/body three times a day for 4 days,
they received blood examinations and collected urine again.
The ethics committee of Kyoto Prefectural University of
Medicine approved the study.
Animal procedures
ApoE−/− mice (C57BL/6J-Apoetm1Unc) were originally
purchased from Jackson Laboratories (Bar Harbor, ME).
ApoE−/− mice were at the 10th backcross into the C57BL/6
background. Mice were maintained on a rodent chow diet
containing 4.5% fat (Oriental BioService, Kyoto, Japan)
and autoclaved acidified (pH 2.8) water before 8 weeks of
age. From 8 (day 57) to 16 (day 113) weeks of age, these
mice were maintained on a “Western” high-fat diet (0.2%
cholesterol, 21% saturated fat; Oriental BioService, Kyoto,
Japan). The atherosclerosis studies were designed to
examine the effect of administration of loxoprofen sodium
during early atherosclerotic lesion formation in apoE−/−
mice. The mice were divided into 3 groups (vehicle group, 7
day loxoprofen sodium group, 56 day loxoprofen sodium
group) at 8 weeks of age (day 57), randomly. Animal care
and experimental procedures were carried out in accordance
with the regulations and with the approval of Kyoto
University’s Animal Care Committee. The mice were
continued on this regimen until 16 weeks of age, when they
were killed with an overdose of sodium pentobarbital.
Administration of loxoprofen sodium or indomethacin to
apoE−/− mice
Randomly selected mice were treated with loxoprofen
sodium (4 mg/kg/day) added to the drinking water from 8
(day 57) to 16 (day 113) weeks of age or from 15 (day 106)
to 16 (day 113) weeks of age. The dose of loxoprofen
sodium used in our study was chosen based on oral dosing
in acute studies of carageenan induced footpad edema
plethysmometry in rats in which the oral ED50 for this
assay in rats is 2 mg/kg, twice a day [13]. The dose of the
drug was calculated on the basis of the average consumption
of water and the body weight, determined weekly. Loxo-
profen sodium was kindly provided by Daiichi-Sankyo, Co.
(Tokyo, Japan).
Urinary thromboxane, prostaglandin I, and prostaglandin
E2 metabolite excretion
As platelet TxA2 metabolite, prostaglandin (PG) I
metabolite, and PGE2 metabolites, we measured urinary 2,3
dinor TxB2, urinary 2,3 dinor 6 keto PGF1α, urinary PGE2
metabolites. From 15 to 16 weeks of age, 24 h urine samples
of mice were collected with metabolic cages (Tecniplast,
Italy). Mouse and human samples were analyzed by a
commercial assay according to the manufacturer’s proce-
dure (Cayman Chemical, MI). Urine creatinine (CRE) was
measured with dry chem system (SRL, Tokyo, Japan).
Determination of the platelet aggregation
ApoE−/− mice were maintained on the “Western” high-fat
diet from 8 to 16 weeks of age and were treated with vehicle
or 4 mg/kg/day of loxoprofen sodium from 15 to 16 weeksM. Hamaguchi et al.
J. Clin. Biochem. Nutr.
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of age. At 90 min after final dose administration, blood
was collected from five mice in each group. Blood was
collected in 12.9 mM sodium citrate and gently agitated at
37°C for 30 min, and centrifuged at 250 g for 15 min to
obtain plasma [14]. Blood samples were also collected
from healthy volunteers in 12.9 mM sodium citrate and
centrifuged at 150 g for 15 min to obtain platelet rich
plasma (PRP) before loxoprofen sodium administration
and after receiving loxoprofen sodium 60 mg/body three
times a day for 4 days. After separation of PRP, tubes were
centrifuged again at 1,200 g for 15 min to obtain platelet
poor plasma.
To measure changes in the light transmission rate, PRP
samples (200 µl) were incubated for 2 min at 37°C, then
with 22.2 µl of adenosine diphosphate (ADP) or collagen
solution for 5 min at 37°C. The intensity of light transmitted
over 5 min was measured using MCM hematoracer 313 (MC
medical. Tokyo, Japan). ADP and collagen solution were
purchased from MC medical (MC medical. Tokyo, Japan).
ADP added at 1, 2, 4, 8 µM in humans and at 0.5, 1, 2, 4 µM
in mice. Similarly, collagen was added at 0.25, 0.5, 1, 2
µg/mL in humans and 0.5, 1, 2, 4 µg/mL in mice. The
pressure rate was standardized using a grading curve pro-
duced by plotting data with four concentrations of agonist
on the x-axis and pressure rate (%) on the y-axis. The
concentration of agonist causing a 50% maximum aggrega-
tion rate was calculated and applied as the platelet aggrega-
tory threshold index (PATI) [14].
Serum lipids and lipoprotein distribution analysis
ApoE−/− mice were maintained on a “Western” high-fat
diet from 8 to 16 weeks of age and were treated with vehicle
or 4 mg/kg/day of loxoprofen sodium from 8 to 16 weeks of
age. The sera were obtained from mice fasted overnight (11
animals from each group). Serum albumin, CRE, and free
fatty acids (FFA) were analyzed with dry chem system
(SRL, Tokyo, Japan). A high performance liquid chromato-
graph (HPLC) system with two tandem gel permeation
columns was used to evaluate the size distribution of plasma
lipoprotein particles (Skylight Biotech, Akita, Japan) [15,
16]. Fast performance liquid chromatography was per-
formed on an HPLC system model 600 (Waters) with a
Sepharose 6 column (Skylight Biotech, Akita, Japan).
Samples were diluted 20 times and analyzed at a flow rate
of 350 µl/min by monitoring the concentrations of total
cholesterol, and triglycerides with absorbance at 550 nm.
Analysis of aortic lesions
The hearts were flushed through the left ventricle, and the
aortic root was obtained for analysis. The hearts were
removed immediately after the mice were killed, rinsed in
cold phosphate buffered saline to remove traces of blood,
and placed in 4% paraformaldehyde overnight. The hearts
were sliced with a scalpel on a plane parallel to the tips of
the atria at the base of the aortic root, according to a
procedure described by Paigen et al. [ 17]. The tissue
was processed and embedded in OTC compound for
histological sectioning by conventional methods. Fifteen
alternate cryosections of 10-mm thickness were collected
from the proximal aorta starting from the beginning of the
aortic sinus and extending 300 µm distally. The sections
were stained with Oil-Red-O and photographed at a
magnification of 400 with an Olympus U-CMAD3 camera
connected to an Olympus BX50 microscope and DXC-
S500/OL digital capture (Olympus, Tokyo, Japan). The
vessel structures were traced and areas calculated in the
computer-digitized images with the Image J program
(National Institutes of Health, MD). Sections from the
aortic arch were used to quantify atherosclerosis (8 animals
from each group). An observer who was blinded to all
other data analyzed the lesions.
Histological examination of lesion morphology
Sections (10 µm) of OCT embedded tissue were acetone
fixed, and endogenous peroxidase activity was quenched
with 0.3% hydrogen peroxide. Serial sections were subjected
to immunostaining with 2 µg/mL goat anti-COX-1 antibody
(Santa Cruz Biotechnology, CA), 2 µg/mL goat anti-COX-2
antibody (Santa Cruz Biotechnology, CA), 5 µg/mL goat
monoclonal antibodies to macrophages (MOMA2) antibody
(AbD Serotec, Oxford, UK), followed by avidin-biotin
rabbit anti-goat antibody (Nichirei, Tokyo, Japan). The
slides were then incubated with 3,3-Diaminobenzidine
tetrahydrochloride (Sigma, MO) and counterstained with
hematoxylin (Wako Pure Chemical Industries, Osaka,
Japan). Isotype-matched controls were stained in parallel
and in all cases showed no significant reactivity (data not
shown). Intensity of COX-1, COX-2, and MOMA2 staining
was measured by determining the maximum density of DAB
stained cells using the Image J program (National Institutes
of Health, MD). Sections from the aortic arch were used
to quantify atherosclerosis (8 animals from each group). A
blinded observer analyzed the lesions.
Statistical analysis
Data are expressed as mean ± SEM. Statistical significance
was calculated in the SPSS statistical package, version
11.0.1 J (SPSS, IL) for Windows. Student’s t test was used
for comparisons between two groups and Dunnett test was
used to for comparisons among more than three groups.
Probability values <0.05 were regarded as significant.Loxoprofen Sodium Reduces Atherosclerosis
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Fig. 1. Inhibition of prostaglandin production in healthy volunteers and apoE−/− mice by loxoprofen sodium. A, B, and C; Urinary
prostaglandin metabolites in apoE−/− mice reconstituted with vehicle (open bars), with loxoprofen sodium (solid bars). From
mice (15 to 16 weeks) given vehicle or loxoprofen sodium, urine samples for 24 h were collected in metabolic cages. Urinary
metabolites of TXB2 (A), PGF1α (B), and PGE2 (C) were analyzed by enzyme immune assay. D, E, and F, Urine was gathered
from 3 healthy men for 24 h before and after receiving loxoprofen sodium 60 mg/body three times a day for 4 days. Urinary
metabolites of TXB2 (D), PGF1α (E), and PGE2 (F) were analyzed by enzyme immune assay. Data were expressed as the average
(mean ± SEM) of the individual (n = 8) assays in each group. CRE indicates creatinine. Student t test was used for comparisons
between two groups and Dunnett test was used for comparisons between two groups.M. Hamaguchi et al.
J. Clin. Biochem. Nutr.
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Fig. 2. Inhibition of platelet aggregation by loxoprofen sodium. Figures show representative % light transmission curves at each
concentration of platelet aggregation stimulative agents. Platelet aggregation was stimulated by adenosine diphosphate (ADP)
and collagen and was quantified with an MCM hematracer 313. Y-axis means % light transmission and X-axis means time.
Black bar on X-axis indicates 5 min. A and B; mouse platelet aggregation with vehicle at day 7, C and D; mouse platelet
aggregation with loxoprofen sodium at day 7, E and F; human platelet aggregation with vehicle at day 4, G and H; healthy
human platelet aggregation with loxoprofen sodium at day 4.Loxoprofen Sodium Reduces Atherosclerosis
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Results
Loxoprofen sodium inhibits platelet thromboxane produc-
tion in apoE−/− mice and healthy humans
To test the effect and the COX-2 selectivity of loxoprofen
sodium, we measured platelet Tx, PGI2, and PGE2 produc-
tion in apoE−/− mice and healthy men. Loxoprofen sodium
inhibited the platelet production of TxA2 metabolite, urinary
TxB2, by 29.0% compared to vehicle in apoE−/− mice
(269.55 ± 77.48 ng/mg CRE vs 929.17 ± 196.29 ng/mg CRE,
p = 0.012), and inhibited the production of urinary TxB2 by
26.2% compared to pre medication in men (0.53 ± 0.10 ng/mg
CRE vs 2.04 ± 0.12 ng/mg CRE, p = 0.001) (Fig. 1A and D).
Loxoprofen sodium inhibited the production of PGE2 meta-
bolite in apoE−/− mice by 9.0% compared to vehicle (1.29 ±
0.29 ng/mg CRE vs 14.49 ± 3.60 ng/mg CRE, p =0 . 0 0 3 ,
respectively), and inhibited the production of urinary PGE2
metabolite by 29.7% compared to pre medication in men
(0.06 ± 0.02 ng/mg CRE vs 0.20 ± 0.03 ng/mg CRE, p =
0.028) (Fig. 1C and F). Loxoprofen sodium also inhibited the
production of PGI2 metabolite, urinary 2,3 dinor 6 keto PGF1α,
in apoE−/− mice by 26.9% compared to vehicle (107.0 ± 17.83
ng/mg CRE vs 397.2 ± 122.1 ng/mg CRE, p<0.001), and
inhibited the production of urinary 2,3 dinor 6 keto PGF1α by
44.0% compared to pre medication in men (1.11 ± 0.04 ng/mg
CRE vs 2.52 ± 0.09 ng/mg CRE, p<0.001) (Fig. 1B and E).
Loxoprofen sodium inhibits platelet aggregation in apoE−/−
mice and healthy humans
Fig. 2 A, B, C and D shows representative results of
mouse platelet aggregation stimulated by ADP or collagen
solutions. Although PATIADP was 1.96 ± 0.66 µM and
PATIcollagen was 2.17 ± 0.44 µg/ml in mice with vehicle, they
were suppressed to >4 µM (n =1 5 ,   p = 0.033), and >4 µg/ml
(n = 15,  p<0.001) after administration of loxoprofen
sodium. Fig. 2 E, F, G and H show representative results of
healthy human platelet aggregation stimulated by ADP or
collagen solutions, respectively. After administration of
loxoprofen sodium, platelet aggregation was suppressed.
Although PATIADP was 1.52 ± 0.39 µM and PATIcollagen was
0.41 ± 0.03 µg/ml in humans before administration of
loxoprofen sodium, they were suppressed to 3.18 ± 1.50 µM
(n =5 ,   p = 0.004), and 1.28 ± 0.50 µg/ml (n =5 ,  p = 0.034)
after its administration.
Loxoprofen sodium does not affect serum levels of total
cholesterol, triglycerides, or free fatty acids in apoE−/− mice
Body weights were unchanged in mice treated with both
loxoprofen sodium and vehicle (Table 1). Dry chem system
demonstrated that the serum levels of albumin, CRE, and
FFA were unchanged in mice treated with loxoprofen
sodium and vehicle. HPLC analysis demonstrated that the
serum levels of total cholesterol and serum triglycerides
were unchanged (Table 1).
Loxoprofen sodium reduces extent of atherosclerosis in
apoE−/− mice
Atherosclerotic lesion area of the aortic root was signifi-
cantly decreased to 41.5% (308,545 ± 36,892 µm2, p<0.001)
in female mice receiving 4 mg/kg/day of loxoprofen sodium
for 56 days and was decreased to 75.6% (487,455 ± 29,623
µm2, p = 0.001) in female mice receiving 4 mg/kg/day of
loxoprofen sodium for 7 days compared to mice treated
with vehicle (644,372 ± 28,314 µm2) (Fig. 3D). Similarly,
atherosclerotic lesion area was significantly decreased to
63.5% (372,145 ± 38,149 µm2,  p = 0.015) in male mice
receiving loxoprofen sodium for 56 days and 84.8%
(432,789 ± 39,236 µm2, p = 0.015) in male mice receiving
it for 7 days compared to mice treated with vehicle (vs
510,117 ± 34,409 µm2) (Fig. 3E).
Table 1. Serum lipid levels in apoE−/− mice treated with vehicle or 4 mg/kg/day loxoprofen sodium from 8 to 16 weeks of age
From the 8th week to 16th week, mice were randomized to receive a western diet and vehicle or 4 mg/kg/day of loxoprofen sodium
(n = 11 animals for each group). Mice were fasted for 4 h, and lipoprotein distribution was determined by HPLC. Serum albumin,
creatinine, and free fatty acids were analyzed with dry chem system. Results are expressed as mean ± SEM. Student t test was used for









N 1 11 1 1 11 1
Body weight [g] 27.3 ± 0.48 27.17 ± 0.34 0.73 21.80 ± 0.91 20.04 ± 0.57 0.12
Albumin [mg/dL] 3.01 ± 0.03 2.94 ± 0.03 0.07 3.12 ± 0.03 3.12 ± 0.04 0.98
Creatinine [mg/dL] 0.07 ± 0.01 0.09 ± 0.01 0.15 0.08 ± 0.01 0.08 ± 0.01 0.98
Free fatty acids [µEQ/L] 662.64 ± 110.4 553.17 ± 117.59 0.51 413.02 ± 58.2 383.19 ± 107.33 0.81
Total cholesterol [mg/dL] 1253.26 ± 51.51 1162.89 ± 52.74 0.23 1045.65 ± 39.81 1091.43 ± 103.33 0.69
Triglycerides [mg/dL] 39.60 ± 6.44 34.95 ± 3.39 0.53 21.11 ± 1.93 21.26 ± 2.15 0.96M. Hamaguchi et al.
J. Clin. Biochem. Nutr.
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Fig. 3. Representative Oil-Red-O stained sections from the proximal aorta of female apoE−/− mice, and quantification of atherosclerotic
lesion area. A, B, and C were representative Oil-Red-O stained sections from the proximal aorta of female apoE−/− mice. (A),
female mice treated with vehicle, (B) female mice with 4 mg/kg/day loxoprofen sodium for 7 days, and (C) female mice with it
for 56 days. Scale bar = 200 µm. E indicated the area of atherosclerotic lesions in male mice receiving vehicle
(510,117 ± 34,409 µm2), loxoprofen sodium (4 mg/kg/day) for 7 days (432,789 ± 39,236 µm2), loxoprofen sodium for 56 days
(372,145 ± 38,149 µm2). Similarly, D indicated those in female mice, with the mean and SEM being 644,372 ± 28,314 µm2,
487,455 ± 29,623 µm2, and 308,545 ± 36,892 µm2, respectively. Individual data were expressed as dots in each group, and the
average was expressed as mean ± SEM. Dunnett test was used to for comparisons with mice receiving vehicle. Horizontal bar
indicated the mean in each group.Loxoprofen Sodium Reduces Atherosclerosis
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Representative Oil-Red-O and hematoxylin stained sec-
tions from the proximal aorta of female mice treated with
vehicle (Fig. 3A), female mice receiving 4 mg/kg/day
loxoprofen sodium for 7 days (Fig. 3B), and female mice
receiving 4 mg/kg/day loxoprofen sodium for 56 days
(Fig. 3C), indicate fatty streak lesions consisting pre-
dominantly of foam cells. The prevalence of Oil-Red-O
stained lesions among arteriosclerotic lesions in male and
female mice with loxoprofen sodium was equal to that in
male and female mice receiving vehicle (Fig. 4A).
Inmunohistochemical analysis of MOMA2, COX-1 and
COX-2 in atherosclerotic lesions of apoE−/− mice
The prevalence of positive staining lesions of MOMA2,
COX-1 and COX-2 in atherosclerotic lesions in female mice
treated with loxoprofen sodium for both 7 days and 56 days
was similar to that in female mice treated with vehicle
(Fig. 4B, C and D).
Fig. 4. The extent of Oil-Red-O stained lesions, and MOMA2, COX-1 and COX-2 positive lesions in atherosclerotic lesions of female
apoE−/− mice. We applied Oil-Red-O stain and immunocytochemical detection of macrophages or COX in female apoE−/− mice
treated with vehicle (open bars), with 4 mg/kg/day loxoprofen sodium for 7 days (gray bars), and for 56 days (solid bars). We
compared the prevalence of Oil-Red-O stained lesions (A). Sections from proximal aorta were stained with monoclonal
antibodies to macrophages (MOMA-2) (B), COX-1 (C) or COX-2 (D). Data were expressed as the average (mean ± SEM).
Dunnett test was used for comparisons among the three groups.M. Hamaguchi et al.
J. Clin. Biochem. Nutr.
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Side effects of loxoprofen sodium in apoE−/− mice
Treatment of apoE−/− mice with 4 mg/kg/day loxoprofen
sodium was well tolerated. The histological examination of
liver, kidney and stomach showed no abnormalities even at
a dose of 8 mg/kg of loxoprofen sodium.
Discussion
Atherosclerotic lesion formation was reduced to 63.5%
and 41.5%, in male and female apoE−/− mice with loxoprofen
sodium compared to control, respectively. However, the
composition of atherosclerotic lesions in mice treated with
loxoprofen sodium differed from that in the mice receiving
vehicle. The extent of Oil-Red-O, COX-1 and COX-2
expression was the same in mice receiving loxoprofen
sodium and vehicle. Loxoprofen sodium reduced the pro-
duction of TxB2 and PGI2, and also reduced platelet aggrega-
tion  in vivo. Loxoprofen sodium has anti-inflammatory
effects and reduced the production of PGE2. Thus, loxo-
profen sodium, a non-selective NSAID, may reduce athero-
sclerotic lesion formation in apoE−/− mice by an anti-
inflammatory effect. It is widely accepted that aspirin
prevent the occurrence of myocardial infarction and/or
ischemic stroke primarily through the inhibition of platelet
aggregation, although their role in the development of fatty
streak lesions remains a matter of debate.
Belton et al. demonstrated that the profile of PG genera-
tion and expression of COX were remarkably similar in
the apoE−/− murine model and human atherosclerosis. In
the apoE−/− murine model and human atherosclerosis, there
is an increase in the biosynthesis of TXA2 and PGI2, with
induction of COX-1 and COX-2 [18]. The COX-2 selec-
tivity of loxoprofen sodium active metabolite (loxoprofen-
SRS)  in vitro (the ratio of COX-1 IC50 /COX-2 IC50)
was 0.35 [19]. Our study indicated that administration of
loxoprofen sodium for apoE−/− mice (4 mg/kg/day) reduced
biosynthesis of PEG2 metabolite to 9.0%, TXA2 metabolite
to 29.0%, and PGI2 metabolite to 26.9%. Moreover,
administration of loxoprofen sodium to healthy men (60 mg/
body, three times a day) reduced the biosynthesis of PGE2
metabolite to 29.7%, TXA2 metabolite to 26.2%, and
PGI2 metabolite to 44.0%. Thus, loxoprofen sodium may
be a well-balanced COX-1 and COX-2 inhibitor, which
contributes to a reduction of atherosclerotic lesion formation.
On the other hand, loxoprofen sodium did not change the
serum levels of total cholesterol or serum triglycerides.
Some COX inhibitors might affect lipid metabolism.
Rofecoxib has been reported to increase the susceptibility
of human LDL-c and cell membrane lipids to oxidative
modification, a hallmark feature of atherosclerosis. Rofecoxib
promoted the non-enzymatic formation of isoprostanes from
biological lipids, which act as important mediators of
inflammation in the atherosclerotic plaque [20]. Celecoxib
does not have these effects. Thus, each NSAID has different
pharmacologic actions [20–22].
In conclusion, loxoprofen sodium, a non-selective NSAID,
reduces atherosclerotic lesion formation in apoE−/− mice by
suppression of PGE2, TxB2 and PGI2. The influence of
COX-2 selective inhibition in atherosclerosis has been
controversial, but non-selective NSAID could reduce
atherosclerotic lesion formation in a murine model. Our
data may provide insights into the mechanisms underlying
the cardiovascular safety of NSAIDs.
Abbreviations
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